Home Newsfeeds Morgan Stanley Maintains Equal-Weight on Haemonetics, Raises Price Target to $70

Morgan Stanley Maintains Equal-Weight on Haemonetics, Raises Price Target to $70

Morgan Stanley analyst Drew Ranieri maintains Haemonetics (NYSE:HAE) with a Equal-Weight and raises the price target from $60 to $70.

byBenzinga Newsdesk

July 1, 2022

1 minute read

Morgan Stanley analyst Drew Ranieri maintains Haemonetics (NYSE:HAE) with a Equal-Weight and raises the price target from $60 to $70.

Why Budweiser Parent Anheuser-Busch InBev’s Shares Are Taking Off Today

By Shivani Kumaresan

May 8, 8:09 AM

Discover why Anheuser-Busch InBev is surging post-earnings! With a 2.6% sales growth in Q1 FY24, beating estimates, the beverage giant showcases resilience amid market shifts.

BUD

News

Cinedigm Rebrands To Cineverse

By Benzinga Newsdesk

May 22, 9:31 AM

New Brand Marks the Transformation to a Pure-play Streaming Entertainment Content and Technology Company Reimagining the Entertainment ExperienceLOS ANGELES, May 22, 2023 /PRNewswire/ -- Cinedigm Corp. (NASDAQ:CIDM)

CIDM

Palantir Q4 Earnings Preview: Will The Data Software Company Deliver On CEO Expectations For A ‘Strong Finish To The Year’?

By Adam Eckert

February 13, 1:31 PM

Palantir Technologies Inc (NYSE: PLTR) is set to report fourth-quarter earnings results after the bell. The stock is up approximately 18% since the start of the year, but it's still down more than 40% since February 2022.

CAH